Scholarlink

<p><i>Neisseria gonorrhoeae</i> (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conducted MenGO, an open-label, randomized controlled trial to evaluate the efficacy, safety, and immunogenicity of 4CMenB against NG in gay and bisexual men (GBM). Participants were randomized 1:1 to receive two doses of 4CMenB, or no vaccine, and were followed for 2 years with 3-monthly visits. 4CMenB vaccination did not significantly reduce gonorrhoea incidence (incidence rate ratio 0.78 (95% confidence interval (CI) 0.40-1.51;<i>p</i> = 0.457), and no study-related serious adverse events occurred. The vaccine was immunogenic against NG, with higher serum bactericidal activity (hSBA) median titres at 6 months in vaccinated compared to unvaccinated participants (4 [interquartile range (IQR) 2-8] vs 2 [IQR 2-2];<i>p</i> = 0.0021). However, hSBA titres did not increase in participants with an NG infection at the time of vaccination (2 [IQR 2-2] to 2 [IQR 2-4];<i>p</i> = 0·999), whereas those without NG infection showed an increase from baseline to 6 months (2 [IQR 2-4] to 6 [IQR 2-16];<i>p</i> = 0.0089). This study is limited by its small sample size based on an assumed vaccine efficacy of &gt;67% and was impacted by the COVID-19 pandemic. These findings provide important information for current 4CMenB vaccines programmes and gonorrhoea vaccine development and implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Caroline Thng,
  • Sharareh Eskandari,
  • Fengyi Jin,
  • Ian Hughes,
  • Andrew E. Grulich,
  • Maree O’Sullivan,
  • Evgeny A. Semchenko,
  • Kate L. Seib

摘要

Neisseria gonorrhoeae (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conducted MenGO, an open-label, randomized controlled trial to evaluate the efficacy, safety, and immunogenicity of 4CMenB against NG in gay and bisexual men (GBM). Participants were randomized 1:1 to receive two doses of 4CMenB, or no vaccine, and were followed for 2 years with 3-monthly visits. 4CMenB vaccination did not significantly reduce gonorrhoea incidence (incidence rate ratio 0.78 (95% confidence interval (CI) 0.40-1.51;p = 0.457), and no study-related serious adverse events occurred. The vaccine was immunogenic against NG, with higher serum bactericidal activity (hSBA) median titres at 6 months in vaccinated compared to unvaccinated participants (4 [interquartile range (IQR) 2-8] vs 2 [IQR 2-2];p = 0.0021). However, hSBA titres did not increase in participants with an NG infection at the time of vaccination (2 [IQR 2-2] to 2 [IQR 2-4];p = 0·999), whereas those without NG infection showed an increase from baseline to 6 months (2 [IQR 2-4] to 6 [IQR 2-16];p = 0.0089). This study is limited by its small sample size based on an assumed vaccine efficacy of >67% and was impacted by the COVID-19 pandemic. These findings provide important information for current 4CMenB vaccines programmes and gonorrhoea vaccine development and implementation.